Literature DB >> 6347437

Diagnostic value of urinary N-acetyl-beta-D-glucosaminidase, its isoenzymes and the fractional excretion of sodium following renal transplantation.

P H Whiting, J Petersen, D A Power, R D Stewart, G R Catto, N Edward.   

Abstract

Daily total urine N-acetyl-beta-D-glucosaminidase activity, isoenzyme profile and fractional excretion of sodium were measured in 13 consecutive renal transplant patients. Rejection episodes were clinically diagnosed in 12 patients, 11 of whom (92%) showed an increased enzymuria either before or during the onset of clinical signs. The ratio of the two major isoenzymes (A/B) fell during 10 episodes (83%) and in six of these (50%) increased levels of the minor isoenzyme forms were observed. Increased fractional excretion of sodium was associated with nine (75%) of the episodes. Increased fractional excretion of sodium with a raised total enzymuria accompanied by a reduced A/B ratio and an increased proportion of the minor isoenzyme forms occurred in eight (67%) of the rejection episodes. The use of these measurements in the diagnosis of episodes of acute rejection in renal transplantation is discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347437     DOI: 10.1016/0009-8981(83)90312-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Noninvasive diagnosis of renal allograft rejections--application of an information-theoretical model.

Authors:  H Heiss; W Wild; R Margreiter; W Pfaller; P Kotanko
Journal:  Klin Wochenschr       Date:  1988-01-04

2.  Enzymuria pattern in early post renal transplant period: Diagnostic usefulness in graft dysfunction.

Authors:  Banibrata Mukhopadhyay; Shashikant Chinchole; Valentine Lobo; Sishir Gang; Mohan Rajapurkar
Journal:  Indian J Clin Biochem       Date:  2004-07

3.  Association between NAG-B and cadmium in urine with no evidence of a threshold.

Authors:  A Bernard; N Thielemans; H Roels; R Lauwerys
Journal:  Occup Environ Med       Date:  1995-03       Impact factor: 4.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.